{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:55:29Z","timestamp":1790063729359,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rdc.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T22:08:53Z","timestamp":1680732533000},"page":"279-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interstitial Lung Disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Cosimo","family":"Bruni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rdc.2023.01.005_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ard.2008.091710","article-title":"Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study","volume":"68","author":"Vonk","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.005_bib4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.005_bib5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/art.40862","article-title":"Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis","volume":"71","author":"Young","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"144","key":"10.1016\/j.rdc.2023.01.005_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0008-2017","article-title":"The role of high-resolution computed tomography in the follow-up of diffuse lung disease: Number 2 in the Series \"Radiology\" Edited by Nicola Sverzellati and Sujal Desai","volume":"26","author":"Elicker","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.005_bib8","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.005_bib10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.005_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.005_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04538-2020","article-title":"Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial","volume":"59","author":"Flaherty","year":"2022","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020154","article-title":"The treatment of lung involvement in systemic sclerosis","volume":"14","author":"Ruaro","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.005_bib14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.005_bib15","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A\u00a0multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"25","key":"10.1016\/j.rdc.2023.01.005_bib16","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 125 3","key":"10.1016\/j.rdc.2023.01.005_bib17","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials","volume":"38","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.005_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.005_bib19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9790","key":"10.1016\/j.rdc.2023.01.005_bib21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.rdc.2023.01.005_bib22","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.005_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acr.24451","article-title":"Evolution of systemic sclerosis-associated interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide","volume":"74","author":"Ciaffi","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"26","key":"10.1016\/j.rdc.2023.01.005_bib24","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.005_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","article-title":"Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience","volume":"13","author":"Miele","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rdc.2023.01.005_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2147\/JMDH.S295478","article-title":"The role of the multidisciplinary health care team in the management of patients with systemic sclerosis","volume":"15","author":"Farina","year":"2022","journal-title":"J\u00a0Multidiscip Healthc"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.005_bib28","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.005_bib29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.01.005_bib30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib31","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.rdc.2023.01.005_bib32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3899\/jrheum.170055","article-title":"Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time","volume":"44","author":"Nihtyanova","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2023.01.005_bib34","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"10103","key":"10.1016\/j.rdc.2023.01.005_bib35","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"McNearney","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib37","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.005_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.rdc.2023.01.005_bib39","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"10.1016\/j.rdc.2023.01.005_bib40","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.005_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","article-title":"An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years","volume":"23","author":"Campochiaro","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.rdc.2023.01.005_bib44","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1093\/rheumatology\/keaa136","article-title":"Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study","volume":"59","author":"Campochiaro","year":"2020","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.005_bib45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2023.01.005_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/annrheumdis-2022-eular.3183","article-title":"POS0890 nintedanib real-life efficacy and safety in systemic sclerosis (SSc)-intertistial lung disease (ILD): an italian multicentre preliminary study","volume":"81","author":"Campochiaro","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib48","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatology"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S2213-2600(21)00163-6","article-title":"Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice","volume":"9","author":"Khanna","year":"2021","journal-title":"Lancet Respir Med. Jun"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.005_bib50","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.01.005_bib51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib52","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S2665-9913(20)30356-8","article-title":"The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis","volume":"3","author":"Bruni","year":"2021","journal-title":"The Lancet Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2023.01.005_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/2397198320971984","article-title":"Patient preferences for systemic sclerosis treatment: a descriptive study within an Italian cohort","volume":"6","author":"El Aoufy","year":"2021","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.rdc.2023.01.005_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac126","article-title":"Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment","author":"Bruni","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2023.01.005_bib57","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.semarthrit.2021.08.001","article-title":"Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process","volume":"51","author":"Roofeh","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.01.005_bib58","doi-asserted-by":"crossref","first-page":"807982","DOI":"10.3389\/fmed.2021.807982","article-title":"Computed tomography predictors of mortality or disease progression in systemic sclerosis-interstitial lung disease: a systematic review","volume":"8","author":"Landini","year":"2021","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.005_bib59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rdc.2023.01.005_bib60","article-title":"High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey","author":"Bruni","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease","volume":"21","author":"Hoffmann-Vold","year":"2020","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.rdc.2023.01.005_bib62","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.005_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.01.005_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2023.01.005_bib65","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1002\/art.42109","article-title":"American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4","volume":"74","author":"Curtis","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2023.01.005_bib66","doi-asserted-by":"crossref","first-page":"rkz044","DOI":"10.1093\/rap\/rkz044","article-title":"The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review","volume":"3","author":"Liem","year":"2019","journal-title":"Rheumatol Adv Pract"},{"issue":"10","key":"10.1016\/j.rdc.2023.01.005_bib67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rdc.2023.01.005_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221116408","article-title":"Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review","volume":"14","author":"Campochiaro","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:32:46Z","timestamp":1760182366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0889857X23000054"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}